Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in refractory adult and juvenile idiopathic inflammatory myopathy
NCT00106184Phase 2Completed
- Sponsor
- University of Pittsburgh
- Start
- Mar 2006
- Primary completion
- Feb 2010
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of rituximab in dermatomyositis (DM), polymyositis (PM) and juvenile dermatomyositis (JDM), sponsored by University of Pittsburgh. Started Mar 2006; status: completed.
02
Drugs
rituximab
03
Conditions
dermatomyositis (DM)polymyositis (PM)juvenile dermatomyositis (JDM)
Beyond the preview
Go deeper on NCT00106184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00106184.